Engagements

Shire acquisition of Dyax

In the US, we advised counsel to Shire on its acquisition of Dyax, a small pharmaceutical company with pipeline products to treat hereditary angioedema (HAE). The deal, reviewed by the FTC, closed with no divestitures.

Related Capabilities

Andrew R. Dick
Vice President

Washington, DC
+1-202-662-3898 adick@crai.com
Peter Boberg
Vice President

Boston
+1-617-425-3175 pboberg@crai.com

Antitrust & Competition
CRA News

CRA named Top 3 Litigation Dispute Advisory Services Consultant in The National Law Journal

CRA’s Chicago Practice is proud to have been ranked as one of the Top 3 Litigation Dispute Advisory Services Consultancies in The National Law Journal’s “Best...
Antitrust & Competition
Articles

Physician Groups - The Next Enforcement Frontier for Healthcare Provider Mergers?

The Federal Trade Commission’s (FTC’s) recent announcement that it will be undertaking a retrospective study of physician group consolidations may signal an...

Explore our thinking

Shire acquisition of Dyax

Meet Our Team

Related Insights

CRA named Top 3 Litigation Dispute Advisory Services Consultant in The National Law Journal

Physician Groups - The Next Enforcement Frontier for Healthcare Provider Mergers?